Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Regulus shares fall after clinical hold news

June 29, 2016 1:43 AM UTC

Regulus Therapeutics Inc. (NASDAQ:RGLS) plummeted $2.47 (49%) to $2.54 on Tuesday after announcing late Monday that FDA placed a full clinical hold on HCV candidate RG-101. Regulus has now reported two cases of jaundice, both severe adverse events, in patients treated with RG-101 (see BioCentury Extra, June 27). ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article